Alan F. Holmer - 30 May 2025 Form 4 Insider Report for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Reporting relationship: Director
Issuer ticker: CRBP
Reported as of: 30 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2025, 16:30:11 UTC
Prior SEC filing: 14 Jun 2024
Source filing: View source filing
Reporting owner signature: /s/ Meghan Houghton, attorney-in-fact for Alan Holmer

Key filing fact

Alan F. Holmer filed Form 4 for Corbus Pharmaceuticals Holdings, Inc. (CRBP) on 02 Jun 2025.

Key facts

This page summarizes Alan F. Holmer's Form 4 filing for Corbus Pharmaceuticals Holdings, Inc. (CRBP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Jun 2025, 16:30.

Change

Previous filing in this sequence was filed on 14 Jun 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001329585 Primary reporting owner

HOLMER ALAN F

Relationship: Director
Address: C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD
Signature: /s/ Meghan Houghton, attorney-in-fact for Alan Holmer
Signature date: 02 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRBP transaction

Common Stock, par value $0.0001 per share

Award

Transaction value: $0
Shares: +4,800
Change %: +82%
Price: $0.000000
Shares after: 10,629
Date: 30 May 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRBP transaction Derivative

Stock options (right to buy)

Award

Transaction value: $0
Shares: +16,000
Change %
Price: $0.000000
Shares after: 16,000
Date: 30 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,000
Exercise price: $7.42
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On May 30, 2025, 4,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.

Footnote F2

This amount includes 4,800 unvested RSUs that were granted on May 30, 2025.

Footnote F3

The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.